Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases

Singh J.A., Saag K.G., Bridges S.L., Et al., 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis, Arthritis Rheumatol, 68, 1, pp. 1-26, (2016)

Fragoulis G.E., Nikiphorou E., Dey M., Et al., 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 82, 6, pp. 742-753, (2023)

Shaw M., Collins B.F., Ho L.A., Et al., Rheumatoid arthritis-associated lung disease, Eur Respir Rev, 24, 135, pp. 1-16, (2015)

Hannah J.R., D'Cruz D.P., Pulmonary complications of systemic lupus erythematosus, Semin Respir Crit Care Med, 40, 2, pp. 227-234, (2019)

Solomon J.J., Olson A.L., Fischer A., Et al., Scleroderma lung disease, Eur Respir Rev, 22, 127, pp. 6-19, (2013)

Bergmans B.J.M., Gebeyehu B.Y., van Puijenbroek E.P., Et al., Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis, Rheumatol Ther, 10, 5, pp. 1147-1165, (2023)

Singh J.A., Wells G.A., Christensen R., Et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2011, 2, (2011)

Minozzi S., Bonovas S., Lytras T., Et al., Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis, Expert Opin Drug Saf, 15, sup1, pp. 11-34, (2016)

Curtis J.R., Patkar N., Xie A., Et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 4, pp. 1125-1133, (2007)

Carbone J., Perez-Rojas J., Sarmiento E., Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor, Curr Infect Dis Rep, 11, 3, pp. 229-236, (2009)

Singh J.A., Saag K.G., Bridges S.L., Et al., 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis, Arthritis Rheumatol, 68, 1, pp. 1-26, (2016)

Fragoulis G.E., Nikiphorou E., Dey M., Et al., 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 82, 6, pp. 742-753, (2023)

Shaw M., Collins B.F., Ho L.A., Et al., Rheumatoid arthritis-associated lung disease, Eur Respir Rev, 24, 135, pp. 1-16, (2015)

Hannah J.R., D'Cruz D.P., Pulmonary complications of systemic lupus erythematosus, Semin Respir Crit Care Med, 40, 2, pp. 227-234, (2019)

Solomon J.J., Olson A.L., Fischer A., Et al., Scleroderma lung disease, Eur Respir Rev, 22, 127, pp. 6-19, (2013)

Bergmans B.J.M., Gebeyehu B.Y., van Puijenbroek E.P., Et al., Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis, Rheumatol Ther, 10, 5, pp. 1147-1165, (2023)

Singh J.A., Wells G.A., Christensen R., Et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2011, 2, (2011)

Minozzi S., Bonovas S., Lytras T., Et al., Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis, Expert Opin Drug Saf, 15, sup1, pp. 11-34, (2016)

Curtis J.R., Patkar N., Xie A., Et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 4, pp. 1125-1133, (2007)

Carbone J., Perez-Rojas J., Sarmiento E., Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor, Curr Infect Dis Rep, 11, 3, pp. 229-236, (2009)